658 results on '"Joe, W."'
Search Results
2. Data from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
3. Supplementary Figure 1 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
4. Supplementary Tables 1-8 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
5. Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
6. Abstract 4916: Spatial analysis of local drug induced changes in tumor microenvironment predicts effective treatment combinations in breast cancer
7. Abstract 5431: 3D multiplexed tissue imaging reconstruction and optimized region-of-interest (ROI) selection through deep learning model of channels embedding
8. Abstract 5630: Robust spatial biomarker discovery through multi-platform multiplex image analysis of breast cancer clinical cohorts
9. Supplementary Table 1 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
10. Data from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
11. Data from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
12. Supplementary Table S1 from Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer
13. Supplementary Figure 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
14. Supplementary Figure 7 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
15. Supplementary Figures S1-S7 from Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform
16. Supplementary Figure 4 from Temporal Dissection of Tumorigenesis in Primary Cancers
17. Supplementary Data from Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer
18. Data from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
19. Supplementary Table 3 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
20. Supplementary Table 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
21. Supplementary Figure 3 from Temporal Dissection of Tumorigenesis in Primary Cancers
22. Supplementary File 4_Reactome Pathway Analysis from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
23. Data from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
24. Supplementary Methods from Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform
25. Supplementary Figure Legends 1-4, Methods from Temporal Dissection of Tumorigenesis in Primary Cancers
26. Supplementary Table 2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
27. Data from Temporal Dissection of Tumorigenesis in Primary Cancers
28. Data from Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform
29. Supplementary Figures S4-S12 from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
30. Supplementary Table 1 from Temporal Dissection of Tumorigenesis in Primary Cancers
31. Supplementary Table 4 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
32. Supplementary Methods from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
33. Supplementary Table 2 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
34. Supplementary Figure Legends 1-5, Table Legends 1-2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
35. Data from Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer
36. Supplementary Table 5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
37. Supplementary File 1_Rank List from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
38. Supplementary Data from Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer
39. Supplementary Figure 4 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
40. Supplementary Table 1 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
41. Supplementary Figure 3 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
42. Supplementary Figure 1 from Temporal Dissection of Tumorigenesis in Primary Cancers
43. Supplementary Materials and Methods from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
44. Supplementary Figure 5 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
45. Supplementary Figure 2 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
46. Supplementary Figure 1 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
47. Supplementary Figure 2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
48. Supplementary Figure 4 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
49. Supplementary Materials and Methods from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
50. Supplementary Figure 1 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.